Darkhive Inc. Awarded $1.25M Contract with Air Force Research Laboratory to Advance Voice-enabled Command and Control System
SAN ANTONIO, Oct. 11, 2023 /PRNewswire/ -- Darkhive Inc. announces it has been selected by the Air Force Research Laboratory, or AFRL, for a Small Business Innovation Research, or SBIR, Phase II contract in the amount of $1,249,350 focused on tactical voice command and control for the Android Team Awareness Kit (ATAK) in order to address the most pressing challenges in the Department of the Air Force (DAF).
About Darkhive Founded in 2021, Darkhive has placed an emphasis on developing affordable, US-manufactured uncrewed systems with open hardware and software interfaces to provide life-saving situational awareness at home and abroad. Darkhive has previously been awarded an SBIR Phase III IDIQ with AFWERX Autonomy Prime, three SBIR Phase IIs, an STTR Phase II with the University of Alaska, an RDT&E contract with the OUSD RE, and an OTA contract with DIU NSIC.
About Air Force Research Laboratory (AFRL)
The Air Force Research Laboratory (AFRL) is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space, and cyberspace force. With a workforce of more than 11,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit: www.afresearchlab.com.
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...
After tens of thousands of NYC children were turned away from "Summer Rising," New York City's popular, free summer enrichment program, Brains & Motion launched a campaign offering camps at NYU for a small fraction of the up-to-$1400 per week price...